BridgeBio Pharma, Inc. Operating Cash Flow
BridgeBio Pharma, Inc. (BBIO) reported Operating Cash Flow of -$268.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- BridgeBio Pharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$71.10M.
- BridgeBio Pharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$197.28M.
- BridgeBio Pharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$56.42M.
- BridgeBio Pharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$109.57M.
- BridgeBio Pharma, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$445.91M.
- BridgeBio Pharma, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$520.73M.
- BridgeBio Pharma, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$527.72M.
- BridgeBio Pharma, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$419.49M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$71.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$268.38M 10-Q · filed 2026-08-10 | -$324.80M derived: sum of 3 quarters · filed 2026-08-10 | -$434.37M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$197.28M 10-Q · filed 2026-05-07 | -$253.70M derived: sum of 2 quarters · filed 2026-05-07 | -$363.27M derived: sum of 3 quarters · filed 2026-05-07 | -$443.95M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$56.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$165.99M derived: sum of 2 quarters · filed 2026-02-24 | -$246.68M derived: sum of 3 quarters · filed 2026-08-10 | -$445.91M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$109.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$190.25M derived: sum of 2 quarters · filed 2026-08-10 | -$389.49M 10-Q · filed 2025-10-29 | -$584.82M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$80.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$279.92M 10-Q · filed 2026-08-10 | -$475.24M derived: sum of 3 quarters · filed 2026-08-10 | -$655.81M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$199.24M 10-Q · filed 2026-05-07 | -$394.56M derived: sum of 2 quarters · filed 2026-05-07 | -$575.13M derived: sum of 3 quarters · filed 2026-05-07 | -$500.42M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$195.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$375.89M derived: sum of 2 quarters · filed 2026-02-24 | -$301.19M derived: sum of 3 quarters · filed 2026-02-24 | -$520.73M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$180.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$105.86M derived: sum of 2 quarters · filed 2025-10-29 | -$325.40M 10-Q · filed 2025-10-29 | -$450.22M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $74.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$144.83M 10-Q · filed 2025-08-05 | -$269.65M derived: sum of 3 quarters · filed 2026-02-24 | -$414.88M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$219.54M 10-Q · filed 2025-04-29 | -$344.36M derived: sum of 2 quarters · filed 2026-02-24 | -$489.58M derived: sum of 3 quarters · filed 2026-02-24 | -$602.93M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$124.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$270.05M derived: sum of 2 quarters · filed 2026-02-24 | -$383.40M derived: sum of 3 quarters · filed 2026-02-24 | -$527.72M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$145.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$258.58M derived: sum of 2 quarters · filed 2024-11-12 | -$402.90M 10-Q · filed 2024-11-12 | -$496.14M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | -$113.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$257.68M 10-Q · filed 2024-08-01 | -$350.92M derived: sum of 3 quarters · filed 2025-02-20 | -$486.08M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | -$144.32M 10-Q · filed 2024-05-02 | -$237.56M derived: sum of 2 quarters · filed 2025-02-20 | -$372.73M derived: sum of 3 quarters · filed 2025-02-20 | -$403.18M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | -$93.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$228.41M derived: sum of 2 quarters · filed 2025-02-20 | -$258.86M derived: sum of 3 quarters · filed 2025-02-20 | -$419.49M 10-K · filed 2025-02-20 |
| 2022-09-30 | -$135.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$165.62M derived: sum of 2 quarters · filed 2023-11-02 | -$326.25M 10-Q · filed 2023-11-02 | -$460.15M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$30.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$191.09M 10-Q · filed 2023-08-03 | -$324.98M derived: sum of 3 quarters · filed 2024-02-22 | -$446.54M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$160.63M 10-Q · filed 2023-05-04 | -$294.53M derived: sum of 2 quarters · filed 2024-02-22 | -$416.09M derived: sum of 3 quarters · filed 2024-02-22 | -$507.80M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$133.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$255.46M derived: sum of 2 quarters · filed 2024-02-22 | -$347.17M derived: sum of 3 quarters · filed 2024-02-22 | -$497.93M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$121.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$213.27M derived: sum of 2 quarters · filed 2022-11-03 | -$364.04M 10-Q · filed 2022-11-03 | -$460.30M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$91.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$242.48M 10-Q · filed 2022-08-04 | -$338.74M derived: sum of 3 quarters · filed 2023-02-23 | -$470.42M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$150.76M 10-Q · filed 2022-05-05 | -$247.03M derived: sum of 2 quarters · filed 2023-02-23 | -$378.71M derived: sum of 3 quarters · filed 2023-02-23 | -$466.56M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$96.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$227.94M derived: sum of 2 quarters · filed 2023-02-23 | -$315.79M derived: sum of 3 quarters · filed 2023-02-23 | -$399.71M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$131.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$219.53M derived: sum of 2 quarters · filed 2021-11-04 | -$303.45M 10-Q · filed 2021-11-04 | -$379.66M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | -$87.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$171.77M 10-Q · filed 2021-08-05 | -$247.97M derived: sum of 3 quarters · filed 2022-02-25 | -$297.97M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | -$83.92M 10-Q · filed 2021-05-06 | -$160.12M derived: sum of 2 quarters · filed 2022-02-25 | -$210.12M derived: sum of 3 quarters · filed 2022-02-25 | -$278.37M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | -$76.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$126.20M derived: sum of 2 quarters · filed 2022-02-25 | -$194.45M derived: sum of 3 quarters · filed 2022-02-25 | -$253.59M 10-K · filed 2022-02-25 |
| 2019-09-30 | -$50.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$118.24M derived: sum of 2 quarters · filed 2020-11-05 | -$177.38M 10-Q · filed 2020-11-05 | -$223.80M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$68.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$127.39M 10-Q · filed 2020-08-11 | -$173.80M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | -$59.14M 10-Q · filed 2020-05-14 | -$105.55M derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | -$46.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$136.64M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | -$90.23M 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | -$40.49M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |